

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LEPU BIOPHARMA CO., LTD.

樂普生物科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2157)

**(1) POLL RESULTS OF THE 2024 SECOND EXTRAORDINARY
GENERAL MEETING HELD ON JANUARY 31, 2024;
(2) RE-ELECTION OF DIRECTORS AND SUPERVISORS;
(3) CHANGE OF EMPLOYEE REPRESENTATIVE SUPERVISOR;
AND
(4) AMENDMENTS TO THE ARTICLES OF ASSOCIATION**

References are made to the announcement of the Company dated January 16, 2024 in relation to, among other things, the Proposed Re-election of Directors, the Proposed Re-election of Supervisors and the Proposed Amendments to the Articles (the “**Announcement**”), and the notice (the “**Notice**”) and the circular (the “**Circular**”) of the 2024 second extraordinary general meeting (the “**EGM**”) of the Company both dated January 16, 2024. Capitalised terms used herein shall have the same meanings as those defined in the Announcement, the Notice and the Circular unless the context requires otherwise.

ATTENDANCE AT THE EGM

The EGM was chaired by Dr. Pu Zhongjie, the chairman of the Board and an executive Director, and was successfully held at Conference Room, Building 7, No. 37 Chaoqian Road, Changping District, Beijing, the PRC on Wednesday, January 31, 2024 at 11:00 a.m.. The EGM was convened in accordance with the requirements of the relevant laws and regulations of the PRC and the Articles of Association, and the poll results of the EGM are lawful and valid.

The Board is pleased to announce that all the resolutions proposed at the EGM as set out in the Notice were duly passed by the Shareholders by way of poll at the EGM.

POLL RESULTS OF THE EGM

The poll results in respect of all the resolutions proposed at the EGM are as follows:

| SPECIAL RESOLUTION | | NO. OF SHARES VOTED (%) | | |
|--------------------|--|-------------------------------|-----------|------------------------|
| | | FOR | AGAINST | ABSTAIN |
| 1. | To consider and approve the resolution on the Proposed Amendments to the Articles. | 1,172,241,145 (99.989850%) | 0 (0%) | 119,000 (0.010150%) |

| ORDINARY RESOLUTIONS | | NO. OF SHARES VOTED (%) | | |
|----------------------|---|-------------------------------|--------------------------|------------------------|
| | | FOR | AGAINST | ABSTAIN |
| 2. | To consider and approve the re-election of: | | | |
| | i. Dr. Pu Zhongjie as an executive Director of the second session of the Board with effect from the date of the EGM for a term of three (3) years; | 1,171,068,371 (99.889814%) | 1,172,771 (0.100036%) | 119,000 (0.010150%) |
| | ii. Dr. Sui Ziyue as an executive Director of the second session of the Board with effect from the date of the EGM for a term of three (3) years; | 1,172,122,547 (99.979734%) | 118,595 (0.010116%) | 119,000 (0.010150%) |
| | iii. Ms. Pu Jue as a non-executive Director of the second session of the Board with effect from the date of the EGM for a term of three (3) years; | 1,171,211,591 (99.902031%) | 1,029,551 (0.087819%) | 119,000 (0.010150%) |
| | iv. Mr. Yang Hongbing as a non-executive Director of the second session of the Board with effect from the date of the EGM for a term of three (3) years; | 1,172,122,547 (99.979734%) | 118,595 (0.010116%) | 119,000 (0.010150%) |
| | v. Mr. Zhou Demin as an independent non-executive Director of the second session of the Board with effect from the date of the EGM for a term of three (3) years; | 1,172,229,445 (99.988852%) | 11,700 (0.000998%) | 119,000 (0.010150%) |
| | vi. Mr. Yang Haifeng as an independent non-executive Director of the second session of the Board with effect from the date of the EGM for a term of three (3) years; and | 1,172,229,445 (99.988852%) | 11,700 (0.000998%) | 119,000 (0.010150%) |
| | vii. Mr. Fengmao Hua as an independent non-executive Director of the second session of the Board with effect from the date of the EGM for a term of three (3) years. | 1,172,092,303 (99.977154%) | 148,842 (0.012696%) | 119,000 (0.010150%) |
| 3. | To consider and approve the re-election of: | | | |
| | i. Mr. Xu Yang as independent Supervisor of the second session of the Supervisory Committee with effect from the date of the EGM for a term of three (3) years; and | 1,172,102,276 (99.978004%) | 138,869 (0.011846%) | 119,000 (0.010150%) |
| | ii. Mr. Yang Ming as Shareholder representative Supervisor of the second session of the Supervisory Committee with effect from the date of the EGM for a term of three (3) years. | 1,172,241,145 (99.989850%) | 0 (0%) | 119,000 (0.010150%) |

| ORDINARY RESOLUTIONS | | NO. OF SHARES VOTED (%) | | |
|----------------------|---|-------------------------------|-----------|------------------------|
| | | FOR | AGAINST | ABSTAIN |
| 4. | To consider and approve the authorisation of the Board to fix the remuneration of the Directors of the second session of the Board. | 1,172,241,145 (99.989850%) | 0 (0%) | 119,000 (0.010150%) |
| 5. | To consider and approve the authorisation of the Board to fix the remuneration of Mr. Xu Yang as independent Supervisor of the second session of the Supervisory Committee. | 1,172,241,145 (99.989850%) | 0 (0%) | 119,000 (0.010150%) |

As more than two-thirds of the votes were cast in favour of the resolution numbered 1 above, this resolution was duly passed as a special resolution of the Company.

As more than one-half of the votes were cast in favour of the resolutions numbered 2 to 5 above, these resolutions were duly passed as ordinary resolutions of the Company.

Notes:

1. As at the date of the EGM, the total number of issued ordinary Shares was 1,659,444,838 Shares (including 1,605,176,474 H Shares and 54,268,364 Domestic Shares), which represented the total number of Shares entitling the Shareholders to attend and vote on the proposed resolutions at the EGM.
2. There were no Shareholders, who, pursuant to Rule 13.40 of the Listing Rules, were required to abstain from voting in favour of any of the proposed resolutions at the EGM, nor were there any Shareholders who were required under the Listing Rules to abstain from voting.
3. None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the EGM.
4. The total number of issued Shares held by the Shareholders in person or their proxies who have attended the EGM and are entitled to vote is 1,172,360,145 Shares, representing approximately 70.65% of the total number of issued Shares as at the date of the EGM.
5. The Company's H Shares registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the EGM for the purpose of vote-taking.
6. All Directors attended the EGM in person or via electronic means.

RE-ELECTION OF DIRECTORS

Pursuant to the passage of the ordinary resolutions numbered 2 and 4 at the EGM, the Board is pleased to announce that:

- (i) Dr. Pu Zhongjie and Dr. Sui Ziyue were re-elected as the executive Directors of the second session of the Board;
- (ii) Ms. Pu Jue and Mr. Yang Hongbing were re-elected as the non-executive Directors of the second session of the Board; and
- (iii) Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua were re-elected as the independent non-executive Directors of the second session of the Board.

The biographical details of the above-mentioned Directors are set out in the Announcement.

RE-ELECTION OF SUPERVISORS

Pursuant to the passage of the ordinary resolutions numbered 3 and 5 at the EGM, the Board is pleased to announce that:

- (i) Mr. Xu Yang was re-elected as independent Supervisor of the second session of the Supervisory Committee; and
- (ii) Mr. Yang Ming was re-elected as Shareholder representative Supervisor of the second session of the Supervisory Committee.

The biographical details of the above-mentioned Supervisors are set out in the Announcement.

CHANGE OF EMPLOYEE REPRESENTATIVE SUPERVISOR

The Board further announces that, as Mr. Wang Jiwei's term of office as employee representative Supervisor of the first session of the Supervisory Committee has expired on December 9, 2023, he has retired from office by rotation at the employees' representative meeting convened on January 31, 2024 (the "**Employees' Representative Meeting**") and will not offer himself for re-election of the second session of the Supervisory Committee. Mr. Wang Jiwei has confirmed that he has no disagreement with the Supervisory Committee, and there are no other matters relating to his retirement as employee representative Supervisor by rotation that need to be brought to the attention of the Shareholders. The Supervisory Committee would like to take this opportunity to express its sincere gratitude to Mr. Wang Jiwei for his contributions to the Company during his tenure as employee representative Supervisor.

The Board is pleased to announce that, with effect from January 31, 2024, Ms. Zhao Lixuan was elected as the employee representative Supervisor of the second session of the Supervisory Committee at the Employees' Representative Meeting convened in accordance with the relevant requirements of the PRC Company Law and the Articles of Association, and whose election was not subject to the approval of the Shareholders. Ms. Zhao Lixuan's biographical details are set out below:

Ms. Zhao Lixuan (趙力萱) ("Ms. Zhao"), aged 32, is the employee representative Supervisor of the Company. Ms. Zhao has served as the investor relations director of the Company since March 2023. Prior to this, Ms. Zhao served as the senior assistant to the deputy general manager, as the investor relations manager and as the investor relations director of Lepu Medical from December 2015 to March 2023.

Ms. Zhao obtained a Bachelor of International Economics and Trade from Zhengzhou University (鄭州大學) in the PRC in July 2014 and a Master of Science (MSc) in Global Marketing from the University of York in January 2016.

The Company has entered into a service contract with Ms. Zhao and the term of office of Ms. Zhao as employee representative Supervisor will be three (3) years effective from the date of the Employees' Representative Meeting at which Ms. Zhao was elected as employee representative Supervisor. Ms. Zhao will not receive any Supervisors' remuneration from the Company during her term as employee representative Supervisor.

Saved as disclosed herein, as at the date of this announcement, Ms. Zhao (i) has not held any other major positions within the Group and has not held any directorships in any other listed companies in Hong Kong or overseas in the last three years; (ii) does not have any interest or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations required to be disclosed pursuant to Part XV of the SFO; and (iii) has no relationships with any other Directors, Supervisors, members of senior management or substantial Shareholders of the Company. Save as disclosed herein, there is no other information required to be disclosed pursuant to Rule 13.51(2)(h) to Rule 13.51(2)(v) of the Listing Rules and there are no other matters that need to be brought to the attention of the Shareholders.

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

The special resolution numbered 1 was passed by the Shareholders at the EGM to approve the Proposed Amendments to the Articles, the details of which are set out in the Circular. Accordingly, the amended Articles of Association shall become effective from the date of the EGM. The full text of the amended Articles of Association will be published on the respective websites of the Company (www.lepubiopharma.com) and the Stock Exchange (www.hkexnews.hk).

By order of the Board
Lepu Biopharma Co., Ltd.
Dr. Pu Zhongjie
Chairman of the Board and Executive Director

Shanghai, the PRC
January 31, 2024

As at the date of this announcement, the Board comprises Dr. Pu Zhongjie (chairman) and Dr. Sui Ziye (chief executive officer) as executive Directors; Mr. Yang Hongbing and Ms. Pu Jue as non-executive Directors; and Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua as independent non-executive Directors.